2 matrix and collagen that mimic the structural framework of real human tissues to which cells can attach and grow may be able to stabilize the circulating metastatic cells. Once the metastatic cells undergo attachment and become adherent, they gain drug sensitivity and can be killed by anticancer drugs that are either administered to the blood or conjugated to the devices.
The cancer stem cells (CSCs) have been highlighted lately, due to the opinion that these CSCs are the culprits for therapeutic resistance, metastasis, and recurrence of the diseases, and therefore, might be selected as the target of treatment [1] [2] [3] [4] . Of the many properties that the CSCs possess, two characteristics came to our attention, i.e., nonadherent, 3-dimentional growth phenotype and high drug resistance. While working on the isolation and maintenance of CSCs, we found that anticancer drug resistance of the cancer cells was associated with their suspended, non-adherent growth pattern. (Fig 1a and 1b) . Later on we accidently found that the adherent phenotype could be acquired to the cells by simply placing the parental cells in a basic serum-free medium (DMEM/F-12/GlutaMax + 1.8% BSA) (Fig 1a-iii and b-iii) . Furthermore, we found that the cancer cells acquired similar non-adherent morphology when cultured in regular medium (5% FBS/SMEM) but in an Ultra Low Attachment Surface (ULAS) plate (polystyrene coated with neutral charged, hydrophilic hydrogel) (Fig 1a-iv μM, though it killed more than 80% of the adherent cells in monolayer attachment growth (Fig 2a) . Similarly, the non-adherent MDA-MB-231 cells were highly resistant to paclitaxel-the drug of choice for breast cancer-at a dose of 8 μM, while it killed almost 90% of the adherent cells (Fig 2b) . The non-adherent cells were also multidrug (Fig 1c) . Moreover, the re-attached cancer cells re-gained response to anticancer drugs just as the adherent cells (Fig 3) .
We don't know why the non-adherent cancer cells are highly resistant at this moment.
We did see, however, that the non-adherent cancer cells expressed a high level of socalled "cancer stem cell markers" such as CD133 and CD44 compared to the adherent cells (Fig 4) 5-7 . Nanog, a transcription factor functioning in maintaining embryo stem cells in the undifferentiated state 8 , survivin, an anti-apoptotic molecule 9, 10 , and thymidylate sythase (TS), a key enzyme involved in the de novo synthesis of DNA which circumvents the efficacy of 5-FU 11, 12 , are also significantly up-regulated in the nonadherent cells (Fig 4a) . 
